RARE
Ultragenyx Pharmaceutical Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.0% ·
share flow +8.0% ·
net new positions -10.5%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 477.97K | $7.18M | +1 | −2 |
| Q2 2026 | 97 | -6 | 59.88M | $1.99B | +8 | −14 |
| Q1 2026 | 106 | +4 | 55.54M | $1.16B | +10 | −7 |
| Q4 2025 | 102 | 0 | 62.50M | $1.44B | +1 | n/a |
| Q3 2025 | 19 | -1 | 45.29M | $1.36B | n/a | −2 |
| Q2 2025 | 18 | -1 | 33.50M | $1.22B | n/a | −1 |
| Q1 2025 | 16 | 0 | 17.22M | $623.52M | n/a | n/a |
| Q4 2024 | 16 | +1 | 16.41M | $690.18M | +1 | n/a |
| Q3 2024 | 14 | +2 | 15.84M | $879.45M | +2 | n/a |
| Q2 2024 | 12 | n/a | 15.75M | $647.24M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 10.13M | -0.8% | $304.79M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | JPMorgan Chase ✦ | 8.02M | n/a | $241.33M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 3 | Fidelity (FMR) ✦ | 7.28M | +179.6% | $219.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 4 | BlackRock ✦ (passive) | 6.43M | +2.7% | $193.27M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 5 | State Street Global Advisors ✦ (passive) | 3.69M | +43.5% | $111.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.31M | -20.0% | $69.49M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Wellington Management ✦ | 1.95M | +3.9% | $58.51M | 0.0% | ▲ Add | 6 | SEC ↗ ×6 |
| 8 | Geode Capital Management ✦ (passive) | 1.58M | -7.7% | $47.55M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | Morgan Stanley ✦ | 910.18K | n/a | $27.38M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 10 | AQR Capital Management ✦ | 746.18K | +195.7% | $22.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 11 | Goldman Sachs Group ✦ | 476.94K | n/a | $14.35M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Adage Capital Partners ✦ | 430.00K | -71.9% | $12.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 330.95K | +779.6% | $9.96M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 326.18K | -43.5% | $9.81M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 237.64K | -56.1% | $7.15M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 16 | Fisher Asset Management ✦ | 168.08K | -9.5% | $5.06M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Marshall Wace ✦ | 146.09K | +121.8% | $4.39M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 18 | Millennium Management ✦ | 99.21K | -79.6% | $2.98M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 21.90K | -89.5% | $658,752 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $35.77M | was 0.0% |
| Point72 Asset Management | $18.76M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 293 holders, 97.86M shares, $1.96B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.07K sh · $107,898
Officer · 1.28K sh · $17,410
Officer · 161 sh · $2,252
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology